We discover, identify and evaluate investigational compounds that show potential to advance the treatment of life-threatening diseases. “The acquisition of Kite establishes Gilead as a leader in cellular therapy and provides a foundation from which to drive continued innovation for people with advanced cancers,” said John F. Milligan, PhD, Gilead’s President and Chief Executive Officer. The Company is developing a pipeline of engineered autologous cell therapy-based product candidates for the treatment of … You will receive a link to create a new password via email. Gilead had been looking for an acquisition to diversify its portfolio beyond its leading position in infectious-disease treatments and provide a new revenue stream as sales of the company’s hepatitis C drugs decline. Gilead’s research and development program is focused on what’s next.

Our pipeline of cancer therapies in the areas of cell therapy, immuno-oncology, and targeted therapies includes investigational therapies and next-generation technologies that have the power to transform the way cancer is treated. Our pipeline of cancer therapies in the areas of cell therapy, immuno-oncology, and targeted therapies includes investigational therapies and next-generation technologies that have the power to transform the way cancer is treated. CAR-T is different from typical small molecule or biologic therapies because it is manufactured for each individual patient using their own cells. Learn about the science of cell therapy, our cancer research, and our cancer treatments in the pipeline. For the latest updates on Gilead’s ongoing response to COVID-19, please click here.

2 Phase 2 study conducted in treatment naïve patients to support virologically suppressed indication. “The field of cell therapy has advanced very quickly, to the point where the science and technology have opened a clear path toward a potential cure for patients. 3 Phase 2 studies are academic collaborations. The deal for Kite would be one of Gilead’s biggest, more than the $11 billion purchase of liver-disease drugmaker Pharmasset in 2012, which provided Gilead with hepatitis C therapies that are among the world’s top-selling drugs. Although several other companies are developing the CAR-T therapies, axi-cel is awaiting an FDA decision for non-Hodgkin lymphoma (that decision is due by November 29).

Its new blood cancer therapy, axi-cel, faces questions about competition, the complexity of its manufacturing process and how it will be paid for by insurers. Some of the content on this page is not intended for users outside the US. ALL - Acute lymphocytic leukemia. Gilead to Buy Kite Pharma and Their CAR-T Pipeline By: Peter Ciszewski | Published on: Aug 28, 2017 With today’s $12 billion purchase of Santa Monica-based Kite Pharma, Gilead has not only validated the CAR-T industry, but also put a price on what the technology is worth. iNHL - Indolent non-Hodgkin lymphoma.

3 Q1’20 representation of program phase based on criteria used by Forty Seven. MCL: Mantle cell lymphoma. Phase 1. Kite is dedicated to curing cancer. iNHL: Indolent non-Hodgkin lymphoma. Kite Pharma, a subsidiary of Gilead Sciences, develops cancer immunotherapy products with a primary focus on genetically engineered autologous T cell therapy with chimeric antigen receptors (CAR-T).. ALL: Acute lymphocytic leukemia. 3 Combination of cilofexor FXR agonist and firsocostat ACC inhibitor (selonsertib no longer included). Some of the content on this page is not intended for users outside the US. Axi-cel: Axicabtagene Ciloleucel.

2 Expected submission and/or approvals in 2021. Axi-cel- Axicabtagene Ciloleucel. Learn more about the medicines in Gilead’s pipeline—medicines that demonstrate the potential to advance the treatment of life-threatening diseases including liver disease, cancer, HIV, and more. Brexu-cel - brexucabtageneautoleucel, formerly KTE-X19. Senators on Trial Diversity, Gilead Sciences Statement on NEJM Publication of Remdesivir Data From NIAID Study, Gilead Sciences Statement on Expanding Global Supply of Investigational Antiviral Remdesivir, Gilead Statement on Complaint Against Federal Government in The Court of Federal Claims, Gilead Sciences Statement on Data From Remdesivir Study in Patients With Severe COVID-19 in China, Gilead Sciences Response to Médecins Sans Frontières, Gilead Sciences Statement on Request to Rescind Remdesivir Orphan Drug Designation, Gilead Sciences Statement on Ensuring Continued Supply of HIV Medicine Amid Coronavirus Outbreak, Gilead Sciences Statement on Access to Remdesivir Outside of Clinical Trials, Gilead Statement on U.S. Patent and Trademark Office Decision to Deny Request for Inter Partes Review of HIV PrEP Patents, Gilead Sciences Statement on the Company’s Ongoing Response to the 2019 Novel Coronavirus (2019-nCoV), Gilead Statement on Commitment to Advancing Descovy for PrEP™ Study in Cisgender Women & Adolescent Females, Gilead Statement on U.S. Government Complaint Regarding HIV PrEP and PEP Patents, Petitions to US Patent and Trademark Office on HIV PrEP Patents, Gilead Sciences Statement on U.S. Preventive Services Task Force 'A' Recommendation for PrEP as an HIV Prevention Strategy.

Kite Pharma is a development-stage biotechnology company designing and developing immune-based therapies to treat cancer indications. We are greatly impressed with the Kite team and what they have accomplished, and share their belief that cell therapy will be the cornerstone of treating cancer. These uses have not been approved by the US Food and Drug Administration or other regulatory authorities.

The safety and efficacy of these investigational agents or investigational uses of marketed products have not been established. With their product likely to new approved by November, Kite has been recognized as an industry leader in the emerging field of cell therapy, which uses a patient’s own immune cells to fight cancer. © 2020 Gilead Sciences, Inc. All rights reserved. Although the approval seems pretty certain, there has been questions about whether Kite could capitalize on the treatment before competition hits the market. We do not share your personal details with anyone. There is no guarantee that these therapies or uses will be commercialized. DLBCL: Diffuse large B-cell lymphoma. These uses have not been approved by the U.S. Food and Drug Administration or other regulatory authorities. Brexu-cel: Brexucabtagene Autoleucel, formerly KTE-X19.

As we look to the future, we remain focused on advancing technologies that could someday address additional hematological malignancies and solid tumors. Kite’s most advanced therapy candidate, axicabtagene ciloleucel (axi-cel), is a CAR T therapy currently under priority review by the U.S. Food and Drug Administration (FDA). ... Report Celebrating Transgender Awareness Week Kite Pharma Harnessing The Immune System ... KITE-718 (MAGE-A3/A6) Solid tumor. Please enter your username or email address. About CAR-T DLBCL - Diffuse large B-cell lymphoma. For the latest updates on Gilead’s ongoing response to COVID-19, please click here. NDA/BLA/MAA, P3 and Registrational P2 Trials, NMEs via In-Licensing, Options, and Product Acquisitions. For the latest updates on our ongoing response to COVID-19, please, Clinical Trials Transparency & Data Sharing Policy, Gilead Sciences Statement on the Solidarity Trial, Statement from Brett Pletcher on Gilead Sciences Settlement Over Charitable Donations, Gilead Remains Committed to Maintaining Advancing Access® Program for HIV Prevention and Treatment Medicines, Gilead Sciences Update on Veklury® (Remdesivir) Manufacturing Network, Gilead Sciences Statement on State Attorneys General Letter on Remdesivir, Gilead Sciences Statement on the Initiation of Clinical Testing of an Inhaled Solution of Remdesivir for Potential Outpatient Treatment of COVID-19, Gilead Sciences Statement on Phase 2/3 Clinical Trial of Remdesivir in Pediatric Patients Hospitalized With COVID-19, Gilead Sciences Statement on Remdesivir Clinical Data, Gilead Sciences Response to U.S. Our similar cultures and histories of driving rapid innovation in order to bring more effective and safer products to as many patients as possible make this an excellent strategic fit.”. The buyout moves Gilead into a leading position in the adoptive cell therapy market, competing with Novartis’ bioengineered T-cell drug CTL019 (which got a favorable decision from an Food and Drug Administration [FDA] Advisory Committee back in July and which should get FDA approval earlier than Kite’s axe-cel). The safety and efficacy of the following investigational compounds or investigational uses of marketed products have not been established. By: Peter Ciszewski|Published on: Aug 28, 2017. The impossible is simply what hasn’t been achieved yet. Axi-cel’s peal sales could be as high as $2 billion per year, but for their $12 Billion that Gilead is also getting a significant pipeline of next generation cancer therapies. © 2020 Gilead Sciences, Inc. All rights reserved.

During the treatment process, T cells are drawn from a patient’s blood and reprogrammed in the manufacturing facility to create T cells that are genetically coded to express a chimeric antigen receptor to recognize and fight cancer cells and other B-cells expressing a specific antigen. The company has developed engineered cell therapies that express either a chimeric antigen receptor (CAR) or an engineered T cell receptor (TCR), depending on the type of cancer.

For the latest updates on our ongoing response to COVID-19, please click here. CLL - Chronic lymphocytic leukemia. MCL - Mantle cell lymphoma. Lost your password? With today’s $12 billion purchase of Santa Monica-based Kite Pharma, Gilead has not only validated the CAR-T industry, but also put a price on what the technology is worth. CLL: Chronic lymphocytic leukemia.

CORC0004 06/20, For Kite medical information, clinical trial inquiries, adverse reactions, and product complaints contact: (844) 454-KITE (5483). 1 European Commission Conditional Marketing Approval and US Emergency Use Authorization granted.